Current vs Average Gross Margin
How the latest reported gross margin of 69.46% compares to its TTM/3Y/5Y/10Y/15Y/20Y averages as of Tuesday, March 31, 2026.
PODD Current vs Average Gross Margin
PODD Gross Margin vs Average
CURRENT VS TTM AVG
-2.38%
CURRENT VS 3Y AVG
-0.44%
CURRENT VS 5Y AVG
+0.35%
CURRENT VS 10Y AVG
+6.38%
CURRENT VS 15Y AVG
+17.90%
CURRENT VS 20Y AVG
+22.34%
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy